Results for tag: "Fecal Microbiome Transplant"

Fecal Microbiome Transplant (FMT), also known as bacteriotherapy or stool transplantation, is a process wherein fecal matter is collected from a tested donor, mixed with a saline or other solution, strained, and then placed in a patient by colonoscopy, endoscopy, sigmoidoscopy, or enema. The objective of FMT is to replace beneficial bacteria that has been eliminated or suppressed, often by the use of antibiotics, thereby restoring the recipient's gut microbiota to a healthy state. This procedure has been most notably used in cases of recurrent Clostridioides difficile infection and is being researched for other conditions such as inflammatory bowel disease, irritable bowel syndrome, and metabolic disorders. Within biotechnology, FMT has emerged as a novel therapeutic approach, reflecting a growing appreciation for the role of the gut microbiome in human health, and has seen a rise in both clinical applications and commercial interest. Biotech companies active in this field are engaged in the research, development, and commercialization of fecal transplant products and methodologies, including proprietary processes to enhance the safety and efficacy of the transplants. Companies involved in the Fecal Microbiome Transplant market include OpenBiome, which was the first public stool bank in the United States; Rebiotix Inc., which focuses on developing microbial-based products; and Finch Therapeutics, which is researching on how to harness the human microbiome to develop therapies. Another player, Vedanta Biosciences, Show Less Read more